Compare Stocks: MAZE, LGND, CGON, and ERAS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$63.82 +0.9%	$73.34	$35.80 ▼ $80.97	$5.66B	0.28	1.10 million shs	516,484 shs
ERAS Erasca	$16.03 +3.7%	$16.51	$2.11 ▼ $24.28	$5.61B	0.61	5.09 million shs	7.77 million shs
LGND Ligand Pharmaceuticals	$301.81 +2.3%	$292.00	$175.89 ▼ $326.63	$6.02B	1.14	275,641 shs	183,044 shs
MAZE Maze Therapeutics	$27.11 +4.8%	$26.85	$21.95 ▼ $53.65	$1.51B	2.16	922,607 shs	670,923 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	-5.28%	-11.36%	-15.18%	+56.77%
ERAS Erasca	0.00%	+8.75%	0.00%	-13.49%	+559.67%
LGND Ligand Pharmaceuticals	0.00%	-0.38%	+4.34%	-4.56%	+63.59%
MAZE Maze Therapeutics	0.00%	+2.57%	+9.23%	-11.32%	-5.18%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$63.82 +0.9%	$73.34	$35.80 ▼ $80.97	$5.66B	0.28	1.10 million shs	516,484 shs
ERAS Erasca	$16.03 +3.7%	$16.51	$2.11 ▼ $24.28	$5.61B	0.61	5.09 million shs	7.77 million shs
LGND Ligand Pharmaceuticals	$301.81 +2.3%	$292.00	$175.89 ▼ $326.63	$6.02B	1.14	275,641 shs	183,044 shs
MAZE Maze Therapeutics	$27.11 +4.8%	$26.85	$21.95 ▼ $53.65	$1.51B	2.16	922,607 shs	670,923 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	-5.28%	-11.36%	-15.18%	+56.77%
ERAS Erasca	0.00%	+8.75%	0.00%	-13.49%	+559.67%
LGND Ligand Pharmaceuticals	0.00%	-0.38%	+4.34%	-4.56%	+63.59%
MAZE Maze Therapeutics	0.00%	+2.57%	+9.23%	-11.32%	-5.18%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.70	Moderate Buy	$87.50	37.10% Upside
ERAS Erasca	2.64	Moderate Buy	$22.09	37.81% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$337.89	11.95% Upside
MAZE Maze Therapeutics	3.08	Buy	$63.40	133.86% Upside

Current Analyst Ratings Breakdown

Latest MAZE, LGND, CGON, and ERAS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	LGND Ligand Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$345.00
9/24/2026	LGND Ligand Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$358.00
9/24/2026	MAZE Maze Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
9/23/2026	MAZE Maze Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$50.00
9/23/2026	LGND Ligand Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$390.00 ➝ $397.00
9/23/2026	MAZE Maze Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$50.00
9/23/2026	MAZE Maze Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$48.00
9/22/2026	MAZE Maze Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$46.00
9/21/2026	LGND Ligand Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
9/21/2026	MAZE Maze Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/8/2026	ERAS Erasca	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$4.04M	1,400.25	N/A	N/A	$9.33 per share	6.84
ERAS Erasca	N/A	N/A	N/A	N/A	$1.05 per share	N/A
LGND Ligand Pharmaceuticals	$268.09M	22.45	$7.85 per share	38.44	$51.68 per share	5.84
MAZE Maze Therapeutics	$167.50M	8.99	N/A	N/A	$7.38 per share	3.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
ERAS Erasca	-$124.55M	-$0.95	N/A	N/A	N/A	N/A	-38.43%	-32.05%	11/11/2026 (Estimated)
LGND Ligand Pharmaceuticals	$124.45M	$9.35	32.28	36.14	2.44	67.88%	20.06%	11.68%	11/5/2026 (Estimated)
MAZE Maze Therapeutics	-$131.12M	-$2.52	N/A	N/A	N/A	N/A	-34.94%	-30.18%	N/A

Latest MAZE, LGND, CGON, and ERAS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	LGND Ligand Pharmaceuticals	$2.26	N/A	N/A	N/A	$77.95 million	N/A
8/11/2026	Q2 2026	ERAS Erasca	-$0.1114	-$0.14	-$0.0286	-$0.14	N/A	N/A
8/11/2026	Q2 2026	MAZE Maze Therapeutics	-$0.76	-$0.76	N/A	-$0.76	N/A	N/A
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/6/2026	Q2 2026	LGND Ligand Pharmaceuticals	$1.97	$2.37	+$0.40	$2.22	$61.30 million	$63.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.22	22.20
ERAS Erasca	N/A	8.29	8.29
LGND Ligand Pharmaceuticals	1.16	31.18	30.96
MAZE Maze Therapeutics	0.09	18.31	18.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
ERAS Erasca	67.78%
LGND Ligand Pharmaceuticals	91.28%
MAZE Maze Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
ERAS Erasca	14.20%
LGND Ligand Pharmaceuticals	5.60%
MAZE Maze Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
ERAS Erasca	103	349.76 million	300.10 million	Optionable
LGND Ligand Pharmaceuticals	47	19.94 million	18.82 million	Optionable
MAZE Maze Therapeutics	141	55.55 million	52.61 million	N/A

MAZE, LGND, CGON, and ERAS Headlines

Recent News About These Companies

MAZE Stock Gets Increased EPS Forecast from HC Wainwright

October 7, 2026 | americanbankingnews.com

HC Wainwright Issues Optimistic Estimate for MAZE Earnings

October 7, 2026 | marketbeat.com

Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

October 6, 2026 | globenewswire.com

Maze Therapeutics, Inc. (MAZE) Interactive Stock Chart - Yahoo Finance

October 6, 2026 | finance.yahoo.com

Research Analysts Set Expectations for MAZE Q2 Earnings

October 6, 2026 | americanbankingnews.com

What is HC Wainwright's Estimate for MAZE Q2 Earnings?

October 6, 2026 | marketbeat.com

3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight (MAZE)

...

October 5, 2026 | marketbeat.com

Allogene Therapeutics (NASDAQ:ALLO) and Maze Therapeutics (NASDAQ:MAZE) Financial Analysis

October 4, 2026 | americanbankingnews.com

Maze Therapeutics' CMO Harold Bernstein Executes 16,141 Share Sale via 10b5-1 Plan

October 4, 2026 | kalkinemedia.comK

Critical Contrast: Fate Therapeutics (NASDAQ:FATE) & Maze Therapeutics (NASDAQ:MAZE)

October 4, 2026 | americanbankingnews.com

Maze Therapeutics Officer Jason V. Coloma Files Form 144 for Proposed Sale of 34,501 Shares

October 3, 2026 | kalkinemedia.comK

Maze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 16,141 Shares of Stock

October 3, 2026 | insidertrades.com

Maze Therapeutics (NASDAQ:MAZE) CEO Jason Coloma Sells 34,501 Shares of Stock

October 3, 2026 | americanbankingnews.com

Maze Therapeutics (NASDAQ:MAZE) Stock: Insider Atul Dandekar Sells 7,500 Shares

October 3, 2026 | americanbankingnews.com

Maze Therapeutics (NASDAQ:MAZE) Stock: Insider Harold Bernstein Sells 16,141 Shares

October 2, 2026 | marketbeat.com

Maze Therapeutics (NASDAQ:MAZE) Stock: Insider Jason Coloma Sells 34,501 Shares

October 2, 2026 | marketbeat.com

Maze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 7,500 Shares of Company Stock

October 2, 2026 | insidertrades.com

Maze Therapeutics (NASDAQ:MAZE) Insider Sells $202,950.00 in Stock

October 1, 2026 | marketbeat.com

Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Average Rating of "Buy" from Analysts

October 1, 2026 | americanbankingnews.com

Maze Therapeutics, Inc. (NASDAQ:MAZE) Stock Has Consensus Price Target of $63.40

October 1, 2026 | marketbeat.com

Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 4.5% - Here's Why

September 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MAZE, LGND, CGON, and ERAS Company Descriptions

CG Oncology NASDAQ:CGON

$63.82 +0.56 (+0.89%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$63.83 +0.01 (+0.02%)

As of 10/9/2026 07:30 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Erasca NASDAQ:ERAS

$16.03 +0.57 (+3.69%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$15.64 -0.39 (-2.43%)

As of 10/9/2026 07:30 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Ligand Pharmaceuticals NASDAQ:LGND

$301.81 +6.81 (+2.31%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$301.82 +0.01 (+0.00%)

As of 10/9/2026 07:30 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Maze Therapeutics NASDAQ:MAZE

$27.11 +1.23 (+4.75%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$27.10 -0.02 (-0.06%)

As of 10/9/2026 07:30 PM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MAZE, LGND, CGON, and ERAS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MAZE, LGND, CGON, and ERAS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MAZE, LGND, CGON, and ERAS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MAZE, LGND, CGON, and ERAS Company Descriptions

CG Oncology NASDAQ:CGON

Erasca NASDAQ:ERAS

Ligand Pharmaceuticals NASDAQ:LGND

Maze Therapeutics NASDAQ:MAZE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MAZE, LGND, CGON, and ERAS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MAZE, LGND, CGON, and ERAS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MAZE, LGND, CGON, and ERAS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MAZE, LGND, CGON, and ERAS Company Descriptions

CG Oncology NASDAQ:CGON

Erasca NASDAQ:ERAS

Ligand Pharmaceuticals NASDAQ:LGND

Maze Therapeutics NASDAQ:MAZE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools